Cipla targets $1 bn US revenue in FY27
Cipla
aims to achieve $1 billion sales in the US by the next fiscal year, driven by the products it has lined up for launch which the Indian drug maker expects will more than compensate for the imminent patent expiry and price erosion on cancer drug Revlimid.
'We believe our pipeline should get us closer to the target (of $1 billion) or surpass that by FY27, depending on the launch timing,' managing director and global chief executive Umang Vohra said over an investor call on Friday.
Explore courses from Top Institutes in
Please select course:
Select a Course Category
Management
others
Finance
Technology
MBA
Degree
PGDM
Cybersecurity
Project Management
Data Science
CXO
Digital Marketing
Design Thinking
Product Management
healthcare
Operations Management
Data Science
Leadership
Data Analytics
Public Policy
MCA
Others
Artificial Intelligence
Skills you'll gain:
Duration:
10 Months
IIM Kozhikode
CERT-IIMK GMPBE India
Starts on
undefined
Get Details
Skills you'll gain:
Duration:
11 Months
IIM Kozhikode
CERT-IIMK General Management Programme India
Starts on
undefined
Get Details
Skills you'll gain:
Duration:
9 Months
IIM Calcutta
CERT-IIMC APSPM India
Starts on
undefined
Get Details
'We have plans for all our launches that are coming in to make up for the revenue losses for Revlimid and that will happen in the short to medium term,' he added. The US remains a very attractive market for Cipla. 'We see it as a growth market over the next 3-5 years,' he said.
A generic version of Revlimid (lenalidomide) is one of Cipla's top-selling products in the US. As part of an out of court settlement,
Cipla
manufactures and markets the drug in the US.
Analysts said the expiry of the drug's patent is expected to significantly impact Cipla through a reduction in revenue and potential margin pressure.
Cipla has a robust pipeline for the US business with respiratory generic Advair closer to commercialisation and is also preparing for launch of generic Symbicort and a couple of inhalation products. It also plans to launch 2–3 peptide assets in FY26.
Timely monetisation of these launches remains critical for the company to offset the lenalidomide generic sales erosion, according to a report by broking firm IIFL.
Vohra sees the respiratory segment and new product launches lined up in the category to be the biggest opportunity for Cipla in the next 12 months. 'We have 3-4 launches coming up for the US alone, we have several coming up for emerging markets and several for India,' he told ET.
About potential US tariffs on the pharma sector, Vohra said he does not see it having a 'debilitating effect'. There will be an impact, but it will not derail the business, he said.
The company on Friday reported a 10% year-on-year increase in consolidated net profit to Rs 1,298 crore for the first quarter ended June. Revenue rose 4% to Rs 6,957 crore and Ebitda was 25.6% of the revenue, the company stated in a filing with stock exchanges.
Its India business delivered growth of 6% year-on-year, topping Rs 3,000 crore for the first time ever in a quarter, contributing 44% to the total revenue.
Revenue from North America was $226 million (about Rs 1,955 crore) supported by traction in differentiated assets. It launched two generic oncology products in the US in the past quarter: nano paclitaxel vials and nilotinib capsules.
'This performance builds on a strong prior year-on-year quarter where we achieved our highest ever US generics revenue,' said Vohra.
Meanwhile, the company has signed an agreement to launch its first biosimilar product in the US that is expected in Q2 FY26.
'We will in-license a few assets through partnerships in the near term and maybe launch our own biosimilar assets around 2029-2030,' Vohra said.
The company is betting big on GLP-1, which controls sugar levels and appetite, and sees it as a 'significant growth driver for its business.'
'For us the entire GLP 1 category is important rather than looking at individual categories within that. It will shape up in a manner depending on pipeline assets,' said Vohra. Cipla aims to be among the first wave of launchers for the drugs. The company plans to have a hybrid strategy including having its own products as well as through partnerships.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India.com
19 minutes ago
- India.com
Bad news for Noel Tata, Rs 78000000000 demand notice to this Ratan Tata company by DoT over…
The Department of Telecom (DoT) has issued a 'show-cause-cum-demand notice' to Tata Communications, seeking approximately Rs 7,800 crore in adjusted gross revenue (AGR) dues, according to an official company note. The demand pertains to AGR liabilities spanning the period from 2005-06 to 2023-24, as outlined in the note dated July 17. Tata Communications On Notice Over AGR dues 'As at June 30, 2025, the company has received 'Show Cause-cum Demand Notices' ('demand notices') from Department of Telecommunications of India aggregating to Rs 7,827.55 crore for financial years ranging from FY 2005-06 to FY 2023-24, which have been revised over a period of time,' Tata Communications Managing Director AS Lakshminarayan said. He said the demand notices include Rs 276.68 crore towards disallowance of deductions claimed by the company on payment basis for the financial year (FY) 2010-11 under ISP (internet service provider) licence and FY07 and FY10 under NLD (national long distance) licence. Tata Communications has existing appeals relating to its ILD (International Long Distance), NLD, and ISP licences that were filed in the past and are pending at the Supreme Court and telecom tribunal TDSAT. Lakshminarayan said the company's appeals are not covered by the apex court judgement dated October 24, 2019, on AGR under the old telecom licence regime called UASL. 'Further, the company believes that all its licences are different from UASL, which was the subject matter of Hon'ble Supreme Court judgement of October 24, 2019. The company, based on its assessment and independent legal opinions, believes that it will be able to defend its position,' Lakshminarayan said. What Is AGR Dues Matter Of Telecom Operators? As per initial calculation by the government, telecom operators had liability to pay around Rs 1.65 lakh crore in total AGR dues till FY19. The calculation as of March 2022 showed that the AGR liability on Bharti Airtel was Rs 31,280 crore, Vodafone Idea Rs 59,236.63 crore, Reliance Jio Rs 631 crore, BSNL Rs 16,224 crore, MTNL Rs 5,009.1 crore up to financial year 2018-19. The government calculation at that time did not include liability on Tata Communications. (With Inputs From PTI)
India.com
19 minutes ago
- India.com
Forget Physical Gold, This RBI Gold Scheme Is Giving Massive 251% Returns
photoDetails english 2938064 The Sovereign Gold Bond (SGB) 2017-18 Series-II, issued on July 28, 2017, matured on July 28, 2025, with a redemption price of Rs 9,924 per gram, reflecting a remarkable 250.67 percent capital gain over the original issue price of Rs 2,830. In addition, investors earned 2.5 percent annual interest, totaling approximately 20 percent over the 8-year tenure. While this interest is taxable, capital gains for individuals upon maturity are exempt from tax. Issued by the RBI for the Government of India, SGBs are a secure and convenient alternative to physical gold, offering market-linked returns without storage risks or making charges. Updated:Jul 28, 2025, 02:37 PM IST Final Redemption Date and Price 1 / 7 The Reserve Bank of India (RBI) has set the final redemption of Sovereign Gold Bond (SGB) 2017-18 Series-II on July 28, 2025, at a price of Rs 9,924 per gram. Calculation of Redemption Price 2 / 7 The redemption price is determined by the simple average of the closing price of gold of 999 purity for the week preceding the date of redemption (July 21–25, 2025), as published by the India Bullion and Jewellers Association Ltd (IBJA). Issuance Details and Returns 3 / 7 This SGB tranche was issued on July 28, 2017, at an issue price of Rs 2,830 per gram (excluding online discount). The final payout provides investors with a 250.67 percent return (Rs 7,094 gain per unit) over the 8-year holding period, excluding interest. Interest Earnings 4 / 7 Investors also earned a 2.50 percent annual interest (paid semi-annually) on the nominal value throughout the tenure, leading to a cumulative interest gain of around 20 percent across the maturity period. Taxation Benefits 5 / 7 Interest income on SGBs is fully taxable as per the Income-tax Act, 1961. Capital gains on maturity are exempt from tax for individuals, making the redemption proceeds tax-free. Indexation benefits are provided if SGBs are transferred before maturity. What Are Sovereign Gold Bonds? 6 / 7 SGBs are government securities denominated in grams of gold, issued by the RBI on behalf of the Government of India. They serve as a paper and digital alternative to physical gold, with cash-based issuance and redemption. Advantages Over Physical Gold 7 / 7 SGBs protect the quantity of gold purchased, offer returns linked to the current market price at redemption, avoid storage risk/costs, and have no concerns about making charges or purity, unlike gold jewelry. Bonds can be held in demat or RBI records, reducing risk of loss.
Time of India
19 minutes ago
- Time of India
Kinetic launches DX e-scooter starting at ₹1.11 lakh
Marking a significant comeback in the Indian two-wheeler market, Kinetic Engineering Ltd . (KEL) on Monday launched the Kinetic DX EV, an electric version of its iconic DX scooter from the 1990s. Developed and manufactured by its electric vehicle arm Kinetic Watts and Volts , DX EV is available in two variants — DX and DX+, priced at ₹1,11,499 and ₹1,17,499 (ex-showroom, Pune), respectively. Bookings are now open on the company's official website, with a refundable booking amount of ₹1,000. According to the company's statement, deliveries will begin in September 2025, with bookings limited to 35,000 units. It is co-developed with Italian designers and comes integrated with segment-first features such as Kinetic Assist, voice alerts, and Easy Flip pillion footrest. The company said DX EV's key highlight is its 37-litre under-seat storage, which it claims is the largest in its class, capable of holding two helmets and additional essentials. 'The legendary Kinetic DX earned a permanent place in the hearts of millions,' said Ajinkya Firodia, Vice Chairman, Kinetic India. 'Reviving this icon was about reintroducing reliability and innovation in a future-ready format. The new DX marks the beginning of a bold new chapter for Kinetic and for India's electric mobility landscape.' Performance and features DX+ is powered by a 2.6 kWh LFP battery (supplied by Range-X) and delivers an IDC range of 116 km and a top speed of 90 kmph. It also features K-Coast regenerative technology, a 60V system, and three riding modes — Range, Power, and Turbo. The scooter comes equipped with a BLDC hub motor producing 4.8 kW peak power, 220mm front disc brake, telescopic front suspension, adjustable rear shock absorbers, and combi-braking system. While the DX+ will be available in five colours — Red, Blue, White, Silver, and Black — the DX variant will come in Silver and Black. The e-scooter will be manufactured at Kinetic's facility in Pune. The company has already infused ₹72 crore into its EV business and committed an additional ₹177 crore for scaling up the DX platform.
